Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Passage Bio Inc chart...

About the Company

passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ãŸ-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to deliver to the brain a functional granulin, or grn, gene encoding progranulin for the treatment of ftd caused by a deficiency of progranulin; and pbkr03, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional galc gene encoding the hydrolytic enzyme galactosylceramidase, for infantile krabbe disease. it has a strategic research collaboration with the trustees of the university of pennsylvania's gene therapy program; and collaboration agreement, and a development services and clinical supply agreement with catalent maryland, inc. the company was fou

Exchange

NASDAQ

Website

passagebio.com

$M

Total Revenue

111

Employees

$82M

Market Capitalization

-0.75

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $PASG News

Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know

11d ago, source: Zacks.com on MSN

Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.Below, we take a ...

Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights

14d ago, source:

Continued momentum in upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations (GRN) ...

Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program

13d ago, source: Business Insider

The official rules and application details are available on Passage Bio’s website in the Careers section at Passage Bio, Inc. – Careers. Applications must be submitted by April 26, 2024 and will be ...

Weight Loss Drugs Threatened by US Effort to Contain China

on MSN ago, source:

Popular weight loss and diabetes drugs are getting caught up in a bid by US lawmakers to reduce the country’s reliance on ...

WuXi AppTec, WuXi Bio Tumble After US Panel Advances Ban Bill

11d ago, source:

WuXi AppTec Co. tumbled after a US Senate committee advanced a bill that may ban Chinese biotech firms from accessing federal ...

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

10d ago, source:

Voyager Therapeutics investors need to be patient as the biotech targets hard to treat Alzheimer's and Parkinson's. Read why ...

Independent Contractor Rule Takes Effect, But Legal Challenges Mount

7d ago, source: The National Law Review

You are responsible for reading, understanding and agreeing to the National Law Review's (NLR’s) and the National Law Forum ...

AnaptysBio Inc.

6d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

National Pi Day 2024: Get a deal whether you prefer apple, cherry or pizza pie

on MSN ago, source:

Pi Day is Thursday, March 14, and Blaze Pizza, Papa John's and others have pizza deals. Specials on pie and Taco Bell's ...

Q4 2023 Aemetis Inc Earnings Call

11d ago, source: 雅虎財經

Todd Waltz; EVP & CFO; Aemetis, Inc. Eric McAfee; Chairman of the Board ... And this year, we generated revenue from the sale of LCFS credits from our aim at US Bio gas operations for the first time ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...